Autoimmune T-cells induced by low dose immune checkpoint blockade could be a powerful therapeutic tool in cancer through activation of eliminative inflammation and immunity
Full Text:Subscribers Only
Tauber AI. A tale of two immunologies. In: Grignolio A, ed. Immunology Today: Three Historical Perspectives under Three Theoretical Horizons. Bologna: Bononia University Press; 2010: 15-34.
Rinkevich B. Primitive immune systems: are your ways my ways? Immunol Rev 2004; 198: 25-35.
Szabados T, Bakacs T. Sufficient to recognize self to attack non-self: Blueprint for a one-signal T cell model. Journal of Biological Systems 2011; 19(2): 299-317.
Szabados T, Tusnady G, Kerepesi C, Bakacs T. Computational simulations show that a self-centered immune model is more realistic than conventional nonself-centered models. arXiv 2017; arXiv:1507.00950v1.
Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 2015; 13: 211.
Bakacs T, Mehrishi JN, Moss RW. Ipilimumab (Yervoy) and the TGN1412 catastrophe. Immunobiology 2012; 217(6): 583-9.
Bakacs T, Mehrishi JN, Szabo M, Moss RW. Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy). Pharmacol Res 2012; 66(2): 192-7.
Slavin S, Moss RW, Bakacs T. Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity. Pharmacol Res 2013.
Bakacs T, Mehrishi JN. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency. Immunobiology 2014; 220: 624-5.
Gett AV, Hodgkin PD. A cellular calculus for signal integration by T cells. Nat Immunol 2000; 1(3): 239-44.
Marchingo JM, Kan A, Sutherland RM, et al. T cell signaling. Antigen affinity, costimulation, and cytokine inputs sum linearly to amplify T cell expansion. Science 2014; 346(6213): 1123-7.
Cohen IR. The cognitive paradigm and the immunological homunculus. Immunol Today 1992; 13(12): 490-4.
Forterre P, Prangishvili D. The major role of viruses in cellular evolution: facts and hypotheses. Curr Opin Virol 2013; 3(5): 558-65.
Witzany G. A perspective on natural genetic engineering and natural genome editing. Introduction. Ann N Y Acad Sci 2009; 1178: 1-5.
Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science 2015; 349(6255): 1483-9.
Klein G. Toward a genetics of cancer resistance. Proceedings of the National Academy of Sciences 2009; 106(3): 859-63.
Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 1997; 65(4): 284-97.
de Magalhaes JP. How ageing processes influence cancer. Nat Rev Cancer 2013; 13(5): 357-65.
Beerenwinkel N, Schwarz RF, Gerstung M, Markowetz F. Cancer evolution: mathematical models and computational inference. Syst Biol 2015; 64(1): e1-25.
Udagawa T. Tumor dormancy of primary and secondary cancers. APMIS 2008; 116(7-8): 615-28.
Guidotti LG, Chisari FV. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 1996; 8(4): 478-83.
Kristensen VN. The Antigenicity of the Tumor Cell - Context Matters. NEnglJMed 2017; 376(5).
Medzhitov R, Janeway CA, Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91(3): 295-8.
Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21: 807-39.
Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol 2015; 33(17): 1974-82.
Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29(36): 4828-36.
Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017; 541(7637): 321-30.
Cohen IR. Activation of benign autoimmunity as both tumor and autoimmune disease immunotherapy: a comprehensive review. J Autoimmun 2014; 54: 112-7.
- There are currently no refbacks.